Patents by Inventor David Tumelty

David Tumelty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides that bind to the erythropoietin receptor
    Patent number: 7528104
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: May 5, 2009
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS
    Publication number: 20090098130
    Abstract: The present invention provides GA targeting compounds which comprise GA targeting agent-linker conjugates linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.
    Type: Application
    Filed: January 4, 2008
    Publication date: April 16, 2009
    Inventors: Curt W. BRADSHAW, Sukumar Sakamuri, Yanwen Fu, Bryan Oates, Joel Desharnais, David Tumelty
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20090048166
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: July 11, 2008
    Publication date: February 19, 2009
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Novel Peptides that Bind to the Erythropoietin Receptor
    Publication number: 20090005292
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: November 11, 2005
    Publication date: January 1, 2009
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, David Tumelty, Guy Lalonde, Palani Balu, Peter J. Schatz, William J. Dower, Anjan Chakrabarti, Yaohua S. Dong, Brian T. Frederick, Nicholas C. Wrighton
  • Peptides that bind to the erythropoietin receptor
    Patent number: 7414105
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: August 19, 2008
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20080108564
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: April 13, 2007
    Publication date: May 8, 2008
    Applicant: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
  • Novel spacer moiety for poly (ethylene glycol) modified peptide based compounds
    Publication number: 20070032408
    Abstract: The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure: —NH—(CH2)?—[O—(CH2)?]?—O?—(CH2)?—Y— wherein ?, ?, ?, ?, and ? are each integers whose values are independently selected.
    Type: Application
    Filed: May 12, 2004
    Publication date: February 8, 2007
    Inventors: Christopher Holmes, David Tumelty, Qun Yin
  • Novel peptides that bind to the erythropoietin receptor
    Publication number: 20070027074
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: May 12, 2004
    Publication date: February 1, 2007
    Applicant: Affymax, Inc.
    Inventors: Christopher Holmes, Qun Yin, Guy Lalonde, Peter Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Peptides that bind to the erythropoietin receptor
    Patent number: 7084245
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: August 1, 2006
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Novel peptides that bind to the erythropoietin receptor
    Publication number: 20060040858
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: October 27, 2005
    Publication date: February 23, 2006
    Applicant: Affymax, Inc.
    Inventors: Christopher Holmes, Qun Yin, Guy Lalonde, Peter Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Novel peptides that bind to the erythropoietin receptor
    Publication number: 20050137329
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: May 12, 2004
    Publication date: June 23, 2005
    Applicant: Affymax, Inc.
    Inventors: Christopher Holmes, Qun Yin, Guy Lalonde, Peter Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Novel poly(ethylene glycol) modified compounds and uses thereof
    Publication number: 20050107297
    Abstract: The present invention relates to a peptide-based compound comprising a peptide moiety and a poly(ethylene glycol) moiety wherein the poly(ethylene glycol) moiety (preferably linear) has a molecular weight of more than 20 KDaltons (preferably from 20 to 60 KDaltons). The peptide moiety may be monomeric, dimeric or oligomeric. Such peptide-based compounds may optional include a linker moiety and/or a spacer moiety.
    Type: Application
    Filed: May 12, 2004
    Publication date: May 19, 2005
    Inventors: Christopher Holmes, David Tumelty, Qun Yin